AZN Astrazeneca Plc

By Tapan Panchal

LONDON--Pharmaceutical company AstraZeneca PLC (AZN.LN) on Friday said the U.S. Food and Drug Administration has approved Lynparza for the treatment of advanced ovarian cancer.

The regulator has approved 400 milligrams capsules of Lynparza as the first monotherapy for patients with advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy.

Write to Tapan Panchal at tapan.panchal@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires